藥明生物(02269.HK)擬按“1拆3”進行股份拆細
格隆匯 9 月 21日丨藥明生物(02269.HK)發佈公告,董事會建議以“1拆3”基準進行股份拆細,股份拆細須待(其中包括)股東於股東特別大會上批准後,方可作實。股份目前在聯交所買賣,每手買賣單位為500股現有股份。股份拆細一經生效,拆細股份的每手買賣單位將維持500股拆細股份。
公告稱,股份拆細將提升公司證券交易的流動性並降低每股股份的交易價格,從而吸引更多投資者並擴大股東基礎。根據該公告日期收市價每股191.10港元,500股現有股份的每手買賣單位市價為9.555萬港元;及假設股份拆細已生效的理論經調整價格每股拆細股份63.70港元,500股拆細股份的每手買賣單位價值為3.185萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.